Solventum Receives FDA Clearance For Combined Use Of Restrata Synthetic Electrospun Fiber Matrix, Solventum V.A.C. Therapy

Benzinga · 1d ago

Solventum (NYSE: SOLV), a leader in advanced wound healing, announced today that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the combined use of Restrata™ Synthetic Electrospun Fiber Matrix and Solventum™ V.A.C.® Therapy*. Following Solventum's acquisition of Acera Surgical in December 2025, this regulatory milestone brings two advanced technologies together into one path to support active wound healing.